Loading...
300357 logo

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.SZSE:300357 Stock Report

Market Cap CN¥11.2b
Share Price
n/a
1Y4.6%
7D0.2%
1D-4.1%
Portfolio Value
View

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.

SZSE:300357 Stock Report

Market Cap: CN¥11.2b

Zhejiang Wolwo Bio-Pharmaceutical (300357) Stock Overview

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. More details

300357 fundamental analysis
Snowflake Score
Valuation1/6
Future Growth1/6
Past Performance5/6
Financial Health5/6
Dividends4/6

300357 Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Zhejiang Wolwo Bio-Pharmaceutical
Historical stock prices
Current Share PriceCN¥21.30
52 Week HighCN¥35.84
52 Week LowCN¥20.28
Beta0.39
1 Month Change-3.75%
3 Month Change-16.47%
1 Year Change4.62%
3 Year Change-36.66%
5 Year Change-64.74%
Change since IPO278.80%

Recent News & Updates

Recent updates

Analysis Article Feb 24

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (SZSE:300357) Shares Could Be 36% Below Their Intrinsic Value Estimate

Key Insights Using the 2 Stage Free Cash Flow to Equity, Zhejiang Wolwo Bio-Pharmaceutical fair value estimate is...
Analysis Article Jan 19

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.'s (SZSE:300357) Price Is Out Of Tune With Earnings

It's not a stretch to say that Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.'s ( SZSE:300357 ) price-to-earnings (or...
Analysis Article Jan 01

Zhejiang Wolwo Bio-Pharmaceutical (SZSE:300357) Has A Pretty Healthy Balance Sheet

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Analysis Article Sep 30

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.'s (SZSE:300357) P/E Is Still On The Mark Following 39% Share Price Bounce

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. ( SZSE:300357 ) shares have had a really impressive month, gaining 39...
Analysis Article Sep 26

These 4 Measures Indicate That Zhejiang Wolwo Bio-Pharmaceutical (SZSE:300357) Is Using Debt Reasonably Well

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Analysis Article Jun 30

Zhejiang Wolwo Bio-Pharmaceutical (SZSE:300357) Has Announced That Its Dividend Will Be Reduced To CN¥0.185

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. ( SZSE:300357 ) is reducing its dividend from last year's comparable...
Analysis Article May 27

Investor Optimism Abounds Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (SZSE:300357) But Growth Is Lacking

When close to half the companies in China have price-to-earnings ratios (or "P/E's") below 31x, you may consider...
Analysis Article May 07

Calculating The Fair Value Of Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (SZSE:300357)

Key Insights Zhejiang Wolwo Bio-Pharmaceutical's estimated fair value is CN¥30.54 based on 2 Stage Free Cash Flow to...
Analysis Article Mar 22

Is Zhejiang Wolwo Bio-Pharmaceutical (SZSE:300357) A Risky Investment?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

Shareholder Returns

300357CN PharmaceuticalsCN Market
7D0.2%-1.3%-1.9%
1Y4.6%-14.5%28.7%

Return vs Industry: 300357 exceeded the CN Pharmaceuticals industry which returned -14.5% over the past year.

Return vs Market: 300357 underperformed the CN Market which returned 28.7% over the past year.

Price Volatility

Is 300357's price volatile compared to industry and market?
300357 volatility
300357 Average Weekly Movement4.1%
Pharmaceuticals Industry Average Movement5.2%
Market Average Movement6.7%
10% most volatile stocks in CN Market10.7%
10% least volatile stocks in CN Market4.1%

Stable Share Price: 300357 has not had significant price volatility in the past 3 months compared to the CN market.

Volatility Over Time: 300357's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20021,808n/awww.wolwobiotech.com

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of diagnostic and therapeutic products for allergic diseases in China and internationally. The company offers Changdi, a skin prick test product and dust mite drops; Changhao, an Artemisia annua pollen allergen sublingual drop; and Changdian, a dust mite skin prick test diagnostic kit. It is also involved in the research and development of cells and natural medicines.

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. Fundamentals Summary

How do Zhejiang Wolwo Bio-Pharmaceutical's earnings and revenue compare to its market cap?
300357 fundamental statistics
Market capCN¥11.15b
Earnings (TTM)CN¥425.83m
Revenue (TTM)CN¥1.09b
26.2x
P/E Ratio
10.3x
P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
300357 income statement (TTM)
RevenueCN¥1.09b
Cost of RevenueCN¥50.63m
Gross ProfitCN¥1.04b
Other ExpensesCN¥610.31m
EarningsCN¥425.83m

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

n/a

Earnings per share (EPS)0.81
Gross Margin95.34%
Net Profit Margin39.18%
Debt/Equity Ratio0.2%

How did 300357 perform over the long term?

See historical performance and comparison

Dividends

1.2%
Current Dividend Yield
31%
Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/27 18:43
End of Day Share Price 2026/06/26 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. is covered by 9 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kai WangCitic Securities Co., Ltd.
Zhu ChenCitic Securities Co., Ltd.
Xiao Wei LinEverbright Securities Co. Ltd.